Skip to main content
SpringerLink
Log in

Chemotherapie des fortgeschrittenen Magenkarzinoms bei älteren Patienten und Risikopatienten

  • Conference paper
Book cover Magenkarzinom

  • 22 Accesses

Zusammenfassung

Das Magenkarzinom ist in der Bundesrepublik die zweithäufigste Todesursache bei den malignen Neoplasien. Pro Jahr sterben 28 von 100000 Einwohner an einem Magenkarzinom [25].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Achterrath W, Raettig R, Franks CR, Seeber S (1984) Aktuelle Cisplatinderivate. Beitr Onkol 18:58–82

    CAS  Google Scholar 

  2. Aisner J, Van Echo DA, Whitacre C, Wiernik PH (1982) A phase I trial of continuous infusion VP16–213 (Etoposide). Cancer Chemother Pharmacol 7: 157–160

    PubMed  CAS  Google Scholar 

  3. Beretta G, Fraschini P, Labianca R, Luporini G (1982) The value of FAM polychemotherapy in advanced gastric carcinoma. (Abstract) Proc Am Soc Clin Oncol 103: C-400

    Google Scholar 

  4. Beretta G, Fraschini P, Labianca R, Arnoldi E, Pancera G, Tedeschi M, Tedeschi L, Luporini G (1986) Weekly 5-fluorouracil (F) versus combination chemotherapy for advanced gastrointestinal carcinomas. A prospective study program. (Abstract) Proc Am Soc Clin Oncol 94: C-367

    Google Scholar 

  5. Biran H, Sulkes A (1984) A possible dose-response relationship in „FAM“ chemotherapy for advanced gastric cancer (abstract). Proc Am Soc Clin Oncol 132: C-515

    Google Scholar 

  6. Bonomi PB, Blessing JA, Stehmann FB, DiSaia PJ, Walton L, Major FJ (1985) Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: A gynecologic oncology group study. J Clin Oncol 3: 1079–1085

    PubMed  CAS  Google Scholar 

  7. Cartei G (1985) 5-Fluorouracil, Adriamycin und Mitomycin C beim metastasierenden Magen-karzinom. In: Nagel GA, Bach F, Bartsch HH (Hrsg) Mitomycin ’85, Aktuelle Onkologie. Zuckerschwerdt, München, S 56–64

    Google Scholar 

  8. Cazap EL, Gisselbrecht Ch, Smith FP, Estevez RA, Alvarez CA, Lagarde C, Hannols A et al (1986) Phase II trials of 5-FU, Doxorubicin, and Cisplatin in advanced, measurable adenocarcinoma of the lung and stomach. Cancer Treat Rep 70: 781–783

    PubMed  CAS  Google Scholar 

  9. Cersosismo RJ, Hong WK (1986) Epirubicin: a review of pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol 4: 425–439

    Google Scholar 

  10. Cocconi G, DeLisi V, Di Blasio B (1982) Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. Cancer Treat Rep 66: 1263–1266

    PubMed  CAS  Google Scholar 

  11. Comis RL (1979) Mitomycin C in gastric cancer. In: Mitomycin C — current status and new developments. Carter SK, Crooke ST (eds) Academic Press, New York, pp 129–137

    Google Scholar 

  12. De Lisi V, Cocconi G, Tonato M, Di Costanzo F, Leonardi F, Soldani M (1986) Randomized comparison of 5-FU alone or combined with carmustine, and mitomycin (BAFMi) in the treatment of advanced gastric cancer: a phase III trial of the Italian clinical research oncology group (GOIRC). Cancer Treat Rep 70: 481–485

    PubMed  Google Scholar 

  13. DeSimone PA, Gams R, Birch R (1986) Phase II evaluation of mitoxantrone in advanced carcinoma of the stomach: a southwestern cancer study group trial. Cancer Treat Rep 70: 1043–1044

    PubMed  CAS  Google Scholar 

  14. Doll DC, Weiss RB, Issell BF (1985) Mitomycin: ten years after approval for marketing. J Clin Oncol 3: 276–286

    PubMed  CAS  Google Scholar 

  15. Dorr RT, Fritz WL (1980) Doxorubicin. Cancer chemotherapy handbook. Elsevier, New York, pp 388–401

    Google Scholar 

  16. Dorr, RT, Fritz WL (1980) Carmustine. Cancer chemotherapy handbook. Elsevier, New York, pp 295–302

    Google Scholar 

  17. Dorr RT, Fritz WL (1980) 5-Fluorouracil. Cancer chemotherapy handbook. Elsevier, New York, pp 435–449

    Google Scholar 

  18. Douglass HO, Trave F, Milliron S, Baroni M, Nava H, Emrich LJ, Rustum YM (1987) A phase II trial of 5-fluorouracil and highdose intravenous leukovorin in gastric carcinoma. J Clin Oncol 5: 1150–1156

    PubMed  Google Scholar 

  19. Douglass HO Jr, Lavin PT, Goudsmit A, Klaasen DJ, Paul AR (1984) An eastern cooperative oncology group evaluation of combinations of methyl-CCNU, mitomycin C, adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). J Clin Oncol 2: 1372–1381

    PubMed  Google Scholar 

  20. Fausti SA, Schechter MA, Rappaport BZ, Rey RH, Mass RE (1984) Early detection of cispla-tin ototoxicity. Cancer 53: 224–231

    Article  PubMed  CAS  Google Scholar 

  21. Figoli F, Galligioni E, Crivellari D, Vaccher E, Lo Re G, Tumolo S, Veronesi A et al (1986) Cisplatin (DDP) in combination with adriamycin (A) and fluorouracil (F) (DAF) in advanced gastric cancer — a phase II study (abstract). Proc Am Soc Clin Oncol 95: C-369

    Google Scholar 

  22. Fornasiero A, Cartei G, Daniele O, Fosser V, Fiorentino MV (1984) FAM2 regimen in disseminated gastric cancer. Tumori 70: 77–80

    PubMed  CAS  Google Scholar 

  23. Franke H (1984) Wesen und Bedeutung der Polypathie und Multimorbidität in der Altersheilkunde. Internist 25: 451–455

    PubMed  CAS  Google Scholar 

  24. Gallmeier WM (1977) Krebstherapie im Alter. MMW 43: 1379–1380

    Google Scholar 

  25. Statistisches Bundesamt Wiesbaden (1984) Gesundheitswesen, Fachserie 12, Todesursachen 1983. Statistisches Bundesamt, Wiesbaden, W Kohlhammer, Stuttgart, S 12–19

    Google Scholar 

  26. Greco FA, Johnson DH, Hande RK, Porter LL, Hainsworth JD, Wolff SN (1985) High-dose Etoposide (VP-16) in small-cell lung cancer. Sem Oncol 12 [Suppl 2]: 42–44

    CAS  Google Scholar 

  27. Haas C, Oishi N, McDonald B, Coltman C, O’Bryan R (1983) Southwest oncology group phase I—III gastric cancer study: 5-fluorouracil, adriamycin, and Mitomcin C ± Vincristine (FAM vs V-FAM) compared to Chlorozotocin (CZT), M-AMSA, and Dihydroxyanthracene-dione (DHAD) with unimpressive differences (abstract). Proc Am Soc Clin Oncol (2) 122: C-478

    Google Scholar 

  28. Haim N, Cohen Y, Honigman J, Robinson E (1982) Treatment of advanced gastric carcinoma with 5-fluorouracil, adriamycin and mitomycin C (FAM). Cancer Chemother Pharmacol 8: 277–280

    Article  PubMed  CAS  Google Scholar 

  29. Haim N, Epelbaum R, Cohen Y, Robinson E (1984) Further studies in the treatment of advanced gastric cancer by 5-fluorouracil, adriamycin (doxorubicin), and mitomycin C (modified FAM). Cancer 54: 1999–2002

    Article  PubMed  CAS  Google Scholar 

  30. Herrmann R, Fritze D, Queißer W, Flechtner H, Ho AD, Schlag P, König H (1984) Chemotherapie des Magenkarzinoms. Dtsch med Wochenschr 109: 1704

    Google Scholar 

  31. Hill BT (1986) Potential of continuous tumor cell lines for establishing patterns of cross-resistance and collateral sensitivity in vitro. Drugs Exp Clin Res 12: 293–298

    PubMed  CAS  Google Scholar 

  32. Hunter CP, Frelick RW, Feldman AR, Bavier AR, Dunlap WH, Ford L, Henson D et al (1987) Selection factors in clinical trials: results from the cummunity clinical oncology program physician’s patient log. Cancer Treat Rep 71: 559–565

    PubMed  CAS  Google Scholar 

  33. Kelsen DP, Magill G, Cheng E, Coonley C, Yagoda A (1982) Phase II trial of etoposide (VP16) in the treatment of upper gastrointestinal malignancies (abstract). Proc Am Soc Clin Oncol 96: C-371

    Google Scholar 

  34. Kim NK (1984) Chemotherapy of advanced gastric carcinoma with 5-fluorouracil, adriamycin, mitomycin (FAM), and 5-fluorouracil, adriamycin, cisplatin (FAP) combinations: experience in Korea. In: Ogawa M, Muggia FM, Rozencweig M (eds) Adriamycin, its expanding role in cancer treatment. Excerpta Medica, Amsterdam, pp 137–145

    Google Scholar 

  35. Klein HO, Wickramanyake PD, Farkh G-R (1986) 5-Fluorouracil (5-FU), adriamycin (ADM), and methotrexate (MTX)-a combination protocol (FAMTX) for treatment of metastasized stomach cancer (abstract). Proc Am Soc Clin Oncol 84: C-325

    Google Scholar 

  36. Kolaric K, Potrebica V, Stanovnik M (1986) Controlled phase III clinical study of 4-epidoxo-rubicin + 5-fluorouracil versus 5-fluorouracil aJone in metastatic gastric and rectosigmoid cancer. Oncology 43: 73–77

    Article  PubMed  CAS  Google Scholar 

  37. Kris MG, Gralla RJ, Clark RA, Tyson LB, Wertheim MS, Kelsen DP (1985) Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3: 1379–1384

    PubMed  CAS  Google Scholar 

  38. Lee YJ, Catane R, Rozencweig M, Bono VH, Muggia FM, Simon R, Staquet MS (1979) Analysis and interpretation of response rates for anticancer drugs. Cancer Treat Rep 63: 1713–1720

    PubMed  CAS  Google Scholar 

  39. Legha SS, Dimery IW (1985) High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity. J Clin Oncol 3: 1373–1378

    PubMed  CAS  Google Scholar 

  40. Leichmann L, MacDonald B, Dindogru A, Samson M (1982) Platinum: a clinical active drug in advanced adenocarcinoma of the stomach (abstract). Proc Am Assoc Cancer Res 110: 430

    Google Scholar 

  41. Levi JA, Dalley DN, Aroney RS (1979) Improved combination chemotherapy in advanced gastric cancer. Br Med J 2: 1471–1473

    Article  PubMed  CAS  Google Scholar 

  42. Levi JA, Fox RM, Tattersall MH, Woods RL, Thomson D, Gill G (1986) Analysis of a prospective randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. J Clin Oncol 4: 1348–1355

    PubMed  CAS  Google Scholar 

  43. Lipschitz DA (1985) Conference: cancer in the elderly: basic science and clinical aspects. Ann Intern Med 102: 218–228

    Article  PubMed  CAS  Google Scholar 

  44. Lopez M, Di Lauro L, Papaldo P, Conti EMS (1986) Treatment of advanced measurable gastric carcinoma with 5-fluorouracil, adriamycin, and BCNU. Oncology 43: 288–291

    Article  PubMed  CAS  Google Scholar 

  45. Lopez M, Perno CF, Di Lauro L, Papaldo P (1984) 5-Fluorouracil, adriamycin, BCNU (FAB) combination chemotherapy for advanced gastric cancer. Cancer Chemother Pharmacol 12: 194–197

    Article  PubMed  CAS  Google Scholar 

  46. Louie AC, Issell BF (1985) Amsacrine (AMSA) — a clinical review. J Clin Oncol 3: 562–592

    PubMed  CAS  Google Scholar 

  47. MacDonald JS, Gunderson LL, Cohn I Jr (1985) Cancer of the stomach. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer, principles and practice of oncology. Lippincott, Philadelphia, pp 534–552

    Google Scholar 

  48. MacDonald JS, Schein PS, Wooley PV, Smythe T, Ueno W, Hoth D, Smith F et al (1980) 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination-chemotherapy for advanced gastric cancer. Ann Intern Med 93: 533–536

    Article  PubMed  CAS  Google Scholar 

  49. Machover D, Goldschmidt E, Chollet P (1986) Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and highdose folinic acid. J Clin Oncol 4: 685–696

    PubMed  CAS  Google Scholar 

  50. Melamed LB, Selim MA, Schuchman D (1985) Cisplatin ototoxicity in gynecologic cancer patients. Cancer 55: 41–43

    Article  PubMed  CAS  Google Scholar 

  51. Moertel CG (1973) Therapy of advanced gastrointestinal cancer with the nitosoureas. Cancer Chemother Rep 4: 27–34

    CAS  Google Scholar 

  52. Moertel CG, Fleming T, O’Connell M, Schutt M, Rubin J (1984) A phase II trial of combined intensive course 5-Fu, adriamycin and cis-platinum in advanced gastric and pancreatic carcinoma. (Abstract) Proc Am Soc Clin Oncol 137: C-535

    Google Scholar 

  53. Moertel CG, Lavin PT (1979) Phase II—III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 63: 1863–1869

    PubMed  CAS  Google Scholar 

  54. Moertel CG, Rubin J, O’Connell MJ, Schutt AJ, Wieand HS (1986) A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 4: 1053–1057

    PubMed  CAS  Google Scholar 

  55. O’Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE (1985) Etoposide (VP-16 213). N Engl J Med 312: 692–700

    Article  PubMed  Google Scholar 

  56. Oshima K, Yamada T, Nonaka T, Aoyama M, Hirose H, Adachi N, Kobayachi S, Udo K (1982) Treatment of advanced G.I. cancer patients with 5-Fu, adriamycin, and mitomycin C (FAM). Proc 13th Intern Cancer Congress Seattle 8–15th Sept, p 665, Abstr 3977

    Google Scholar 

  57. Osswald H, Kunz W (1987) Therapeutic synergism of Etoposide and Fuororouracil combined sequentially in advanced leukemia L1210. (Abstract) Cancer Res Clin Oncol 113 [suppl]: 53 D-THER 39

    Google Scholar 

  58. Ozols RF, Ostchega Y, Myers CE, Young RC (1985) High-dose cisplatin in hypertonic saline in refractory ovarian carcinoma. J Clin Oncol 3: 1246–1250

    PubMed  CAS  Google Scholar 

  59. Pannettiere FJ, Haas Ch, McDonald B, Costanzi JJ, Talley RW, Athens J, Oishi N et al (1984) Drug combinations in the treatment of gastric adenocarcinoma: a randomized southwest oncology group study. J Clin Oncol 2: 420–424

    Google Scholar 

  60. Preusser P, Achterrath W, Niederle N, Seeber S (1985) Cisplatin. Arzneimitteltherapie 2: 50–65

    Google Scholar 

  61. Preusser P, Wilke H, Achterrath W, Neuhaus B, Balleisen L, Meyer L, van de Loo J (1986) Advanced inoperable stomach cancer: a pilot study with the combination etoposide, adriamycin, and cisplatin. Anticancer Res 6: 1195–1196

    PubMed  CAS  Google Scholar 

  62. Preusser P, Wilke H, Achterrath W, Fink U, Meyer J, Schmitz-Hübner U, Bünte H (1987) Advanced gastric carcinoma: a phase II study with etoposide (E), adriamycin (A), and split course cisplatin (P) = EAP. (Abstract) Proc Am Soc Clin Oncol 6: 292

    Google Scholar 

  63. Queißer W, Flechtner H (1986) Chemotherapy of advanced gastric carcinoma. Onkologie 9: 319–331

    Article  PubMed  Google Scholar 

  64. Radice PA, Bunn PA, Ihde DC (1979) Therapeutic trials with VP-16–213 and VM-26: Active agents in small cell lung cancer, non-hodgkin’s lymphomas, and other malignancies. Cancer Treat Rep 63: 1231–1239

    PubMed  CAS  Google Scholar 

  65. Robinson E, Haim N, Epelbaum R, Cohen Y (1985) Phase II trials in the treatment of advanced gastric cancer I — 5-fluorouracil, adriamycin and mitomycin (FAM), II — cisplatin, adriamycin and 5-fluorouracil (DAF). (Abstract) Proc Am Soc Clin Oncol 77: C-300

    Google Scholar 

  66. Roelofs RI, Hrushesky W, Rogin J, Rosenberg L (1984) Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 34: 934–938

    Article  PubMed  CAS  Google Scholar 

  67. Rougier P, Droz JP, Amiel JL, Ruffier P, Theodore C, Kac J, Chavy A (1985) Gastric carcinoma: a phase II trial of chemotherapy with association 5-fluorouracil (5 FU), adriamycin (ADR) and cisplatin (DDP) (FAP protocol) in metastasized or inoperable patients. Preliminary results. Cancer Chemother Pharmacol 14 [Suppl]: 54–59

    Google Scholar 

  68. Schaefer SD, Post JD, Close LG, Wright CG (1985) Ototoxicity of low- and moderate-dose cisplatin. Cancer 56: 1934–1939

    Article  PubMed  CAS  Google Scholar 

  69. Schein PS, MacDonald JS, Hoth D, Wooley PV (1978) Mitomycin C: experience in the United States, with emphasis on gastric cancer. Cancer Chemother Pharmacol 1: 73–75

    Article  PubMed  CAS  Google Scholar 

  70. Schmoll HJ, Niederle N, Achterrath W (1981) Etoposid (VP-16–213). Klin Wochenschr 59: 1177–1188

    Article  PubMed  CAS  Google Scholar 

  71. Schnitzler G, Queißer W, Heim ME, König H, Katz R, Fritze D, Herrmann R et al (1986) Phase III study of 5-Fu and carmustine versus 5-Fu, carmustine, and doxorubicin in advanced gastric cancer. Cancer Treat Rep 70: 477–479

    PubMed  CAS  Google Scholar 

  72. Seeber S, Osieka R, Schmidt CG, Achterrath W, Crooke ST (1982) In vivo resistance towards Anthracyclines, Etoposide, and cis-diaminedichloroplatinum (II). Cancer Res 67: 4719–4725

    Google Scholar 

  73. The Gastrointestinal Tumor Study Group (1979) Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 63:1871–1876

    Google Scholar 

  74. The Gastrointestinal Tumor Study Group (1984) Randomized study of combination chemotherapy in unresectable gastric cancer. Cancer 53: 13–17

    Article  Google Scholar 

  75. Tozak LK, Von Hoff DD (1984) The cardiotoxicity of anticancer agents. In: Perry MC, Yabro JW (eds) Toxicity of chemotherapy. Grune & Stratton, Orlando, pp 199–226

    Google Scholar 

  76. Vermorken JB, Kapteijn TS, Hart AAM, Pinedo HM (1983) Ototoxicity of cis-diamminedi-chloroplatinum (II): influence of dose, schedule, and mode of administration. J Cancer Clin Oncol 19: 55–58

    Google Scholar 

  77. Vestal RE (1978) Drug use in the elderly: a review of problems and special considerations. Drugs 16: 358–382

    Article  PubMed  CAS  Google Scholar 

  78. WHO (1979) Handbook for reporting results of cancer treatment. WHO Offset Publication No.48, World Health Organization, pp 1–45

    Google Scholar 

  79. Wagener DJTh, Yap SH, Wobbes T, Burghouts JTM, van Dam FE, Hillen HFP, Hoogendoorn GJ et al (1985) Phase II trial of 5-fluorouracil, adriamycin, and cisplatin (FAP) in advanced gastric cancer. Cancer Chemother Pharmacol 15: 86–87

    Article  PubMed  CAS  Google Scholar 

  80. Wälder S, Green M, Muggia F (1985) The role of anthracyclines in the treatment of gastric cancer. Cancer Treat Rev 12: 105–132

    Article  Google Scholar 

  81. Waterhouse JAH (1985) Epidemiology of gastric cancer. In: Preece PE, Cuschieri A, Wellwood JM (eds) Cancer of the stomach. Grune & Stratton, London, pp 1–32

    Google Scholar 

  82. Weiss RB, Issell BF (1982) The nitrosoureas: carmustine (BCNU) and lomustine (CCNU). Cancer Treat Rev 9: 313–330

    Article  PubMed  CAS  Google Scholar 

  83. Weiss RB, Sarosy G, Clagett-Carr K, Russo M, Leyland-Jones B (1986) Anthracycline analogs: the past, present, and future. Cancer Chemother Pharmacol 18: 185–197

    Article  PubMed  CAS  Google Scholar 

  84. Wilke H, Preusser P, Achterrath W, Lenaz L, Stahl M, Schöber Chr, Mayer H-J, Link H, Schmoll H-J (1988) Leukovorin/etoposide/5-fluorouracil in patients during cardiac risks or elderly patients suffering from advanced gastric carcinoma — a phase I/II study. Submitted to Cancer Treat Rep.

    Google Scholar 

  85. Wils J, Bleiberg H, Dalesio O, Blijham G, Mulder N, Planting A, Splinter Z, Duez N (1987) An EORTC gastrointestinal group evaluation of the combination of sequential methotrexate and 5-Fluorouracil, combined with adriamycin in advanced measurable gastric cancer. J Clin Oncol 4: 1799–1803

    Google Scholar 

  86. Wiltshaw E (1983) Chemotherapy of ovarian malignancies at the Royal Marsden Hospital. In: Bender HG, Beck L (eds) Carcinoma of the ovary. Fischer, Stuttgart, pp 169–170

    Google Scholar 

  87. Wiltshaw E, Evans B, Rustin G, Baker J, Barker G (1986) A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma. J Clin Oncol 4: 722–729

    PubMed  CAS  Google Scholar 

  88. Wooley P, Smith F, Estevez R, Gisselbrecht C, Alvarez C, Boiron M, Machado C et al (1981) A phase II trial of 5-Fu, adriamycin and cisplatin (FAP) in advanced gastric cancer. (Abstract) Proc Am Soc Clin Oncol 455: C-481

    Google Scholar 

Download references

Authors
  1. P. Preusser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Wilke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Achterrath
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. U. Fink
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Medizin/Abteilung Gastroenterologie, Allgemeines Krankenhaus Celle, D-3100, Celle, Deutschland

    J. Hotz

  2. Zentrum für Chirurgie, Medizinischen Hochschule Hannover, Konstanty-Gutschow-Str. 8, D-3000, Hannover 61, Deutschland

    H.-J. Meyer

  3. Abteilung Hämatologie - Onkologie, Medizinische Hochschule Hannover, Konstanty-Gutschow-Str. 8, D-3000, Hannover 61, Deutschland

    H.-J. Schmoll

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Preusser, P., Wilke, H., Achterrath, W., Fink, U. (1989). Chemotherapie des fortgeschrittenen Magenkarzinoms bei älteren Patienten und Risikopatienten. In: Hotz, J., et al. Magenkarzinom. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-22121-1_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-22121-1_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-19001-1

  • Online ISBN: 978-3-662-22121-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation